Probiotics and the Treatment of Parkinson's Disease: An Update
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a progressive neurological disorder characterized by motor and non-motor features. Although some progress has been made in conventional PD treatments, these breakthroughs have yet to show high efficacy in treating this neurodegenerative disease. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. Probiotics have putative anticancer, antioxidative, anti-inflammatory, and neuroprotective effects. Multiple lines of evidence show that probiotics control and improve several motor and non-motor symptoms in patients and experimental animal models of PD. Probiotic supplementation mediates these pharmacological effects by targeting a variety of cellular and molecular processes, i.e., oxidative stress, inflammatory and anti-inflammatory pathways, as well as apoptosis. Herein, we summarize the effects of probiotics on motor and non-motor symptoms as well as various cellular and molecular pathways in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, modulation of the microbiota-gut-brain axis using probiotics could be a promising complementary approach to traditional methods to prevent or counteract these disorders, including PD, as widely reported in literature [315,317,318,319,320].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [318]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.018 · Cited by 398
Self-citationRetractedTamtaji, O. R., Kouchaki, E., Salami, M., Aghadavod, E., Akbari, E., Tajabadi-Ebrahimi, M., & Asemi, Z. (2017) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1347074 · Cited by 116
Self-citationRetractedParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410 · cited 4×
“PD is characterized by motor and non-motor features (Sveinbjornsdottir 2016).”
BackgroundInfluentialThe role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Microbiota and neurodevelopmental windows: implications for brain disorders
Borre, Y. E., O’Keeffe, G. W., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.05.002 · Cited by 1,089
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047
Doron, S., & Snydman, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ085 · Cited by 942
Research works printed but not linked: 1
- Mirzanaeni S, Pakpour B, Navabian M (2019) The treatment effect of probiotic Bacillus coagulans on male Parkinson’s rats. J Appl Microbiol Food Ind 5(3):17–30
Cited by
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Bicknell, B. T., Liebert, A. D., Borody, T. J., Herkes, G., McLachlan, C. S., & Kiat, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119577 · Cited by 147
“Probiotic studies have shown substantial improvements in multiple animal models of neurodegenerative [231,369–373] and neurodevelopmental diseases [374,375], PD [371,376], and cognitive decline [377] and reductions in symptoms in MS [378], ALS [379], and ASD [380].”
Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial
Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2305 · Cited by 128
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Ağagündüz, D., Bingöl, F. G., Çelik, E., Cemali, Ö., Özenir, Ç., Özoğul, F., & Capasso, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03609-y · Cited by 82
Metadata
- Authors
- Mirzaei, H., Sedighi, S., Kouchaki, E., Barati, E., Dadgostar, E., Aschner, M., & Tamtaji, O. R.
- Affiliations
- Kashan University of Medical Sciences (IR)
- Islamic Azad University, Tehran (IR)
- Isfahan University of Medical Sciences (IR)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Tamtaji, Omid Reza
- ORCID
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2021-07-20
- Volume
- 42
- Issue
- 8
- Pages
- 2449-2457
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC8770674
- OpenAlex
- W3185323608
- Cited by
- 57
- References
- 91
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 6 · 2022: 4 · 2021: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Environmental Health Sciences (R01ES007331, R01ES010563)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- probiotics, Parkinson's disease, neuroprotection, oxidative stress, neuroinflammation, apoptosis, motor symptoms, non-motor symptoms, gut-brain axis, anti-inflammatory activity, antioxidant activity
- MeSH terms
- Animals, Anti-Inflammatory Agents, Parkinson Disease, Neuroprotective Agents, Neurodegenerative Diseases, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Probiotics and the Treatment of Parkinson's Disease: An Update. https://app.cochat.ai/papers/10.1007/s10571-021-01128-w
- The paper
- Mirzaei, H., Sedighi, S., Kouchaki, E., Barati, E., Dadgostar, E., Aschner, M., & Tamtaji, O. R. (2022). Probiotics and the Treatment of Parkinson's Disease: An Update. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-021-01128-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.